Article
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
Journal of the National Cancer Institute - 1 Apr 2018
Huang Yueye, Qu Shen, Zhu Guangwu, Wang Fei, Liu Rengyun, Shen Xiaopei, Viola David, Elisei Rossella, Puxeddu Efisio, Fugazzola Laura, Colombo Carla, Jarzab Barbara, Czarniecka Agnieszka, Lam Alfred K, Mian Caterina, Vianello Federica, Yip Linwah, Riesco-Eizaguirre Garcilaso, Santisteban Pilar, O'Neill Christine J, Sywak Mark S, Clifton-Bligh Roderick, Bendlova Bela, Sýkorová Vlasta, Xing Mingzhao
Abstract excerpt
Background: Precise risk stratification-based treatment of solitary intrathyroidal papillary thyroid cancer (SI-PTC) that is larger than 1.0 cm and 4.0 cm or less is undefined. Methods: A genetic-clinical risk study was performed on BRAF V600E in 955 patients (768 women and 187 men) with SI-PTC, with median age of 46 years and median clinical follow-up time of 64 months at 11 medical centers in six countries. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
